Nutriband Inc.
NASDAQ:NTRBBiotechnology
+$0.85 today
- Market cap
- $58.59M
- Beta
- 1.97
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.66
Volume 0.03M
Average 0.01M
NTRB Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Nutriband Inc.NASDAQ: NTRB
Financing Cash Flow · Q1 FY2026 · quarter ended Apr 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $5.57K (cash outflow) rose 4.6% year over year, behind the +3417.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +223.2% a year.
Context
- Financing cash flow amounted to 265.3% of revenue in FY2025, down 133.6 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +4.6% toward the trailing-twelve-month pace of +3417.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 5.4M USD
- Year-over-year change
- -36.7%
- 4-year CAGR
- -8.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-31 | 5.4M | -36.7% |
| FY2024 | 2025-01-31 | 8.54M | +309.1% |
| FY2023 | 2024-01-31 | 2.09M | +1203.6% |
| FY2022 | 2023-01-31 | 160.07K | -97.9% |
| FY2021 | 2022-01-31 | 7.63M | — |
Financing Cash Flow vs competitors
How NTRB compares with its peers on the latest reported figures
- NTRB's LTM Apr 2026 financing cash flow of $5.4M is the 4th largest of the 9 companies compared; the peer median is $94.5K.
- Its year-over-year change of +3417.5% is the 3rd highest of 8, against a peer median of +70.1%.
- Financing cash flow amounts to 299.7% of revenue for NTRB, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $250.14M | +95540.9% | +27.6% | — | |
| LTM Mar 2026 | $75.28M | +53361.2% | +21.9% | — | |
| LTM Mar 2026 | $26.46M | +70.1% | — | — | |
| LTM Apr 2026 | $5.4M | +3417.5% | +223.2% | 299.7% | |
| LTM Jun 2024 | $2.15M | — | -37.1% | 264.1% | |
| LTM Mar 2026 | $2.09M | -102.2% | +0.9% | 3.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $439K | -100.4% | — | — |
| LTM Mar 2026 | $189K | -99.9% | — | 2.1% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| Peer median (excluding NTRB) | $94.5K | +70.1% | +11.4% | 3.2% | |
Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Jan 2024 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | (6.18M) | (4.48M) | (5.49M) | (10.48M) | (8.23M) |
| Depreciation & Amortization | 318.26K | 368.96K | 287.72K | 285.05K | 193.8K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 897.83K | 732.13K | 742.7K | 1.54M | 104.4K |
| Change in Working Capital | (541.38K) | (219.32K) | 223.22K | 34.09K | 126.81K |
| Accounts Receivables | 42.97K | (41.67K) | (153.97K) | 74.8K | (44.56K) |
| Inventory | (78.8K) | (97.69K) | 60.73K | (43.44K) | 94.05K |
| Accounts Payables | (145.26K) | (104.86K) | 198.89K | 23.61K | 120.94K |
| Other Working Capital | (360.29K) | 24.9K | 117.57K | (20.89K) | (43.63K) |
| Other Non-Cash Items | 2.23M | 614.51K | 704.17K | 3.99M | 2.67M |
| Operating Cash Flow | (2.81M) | (2.99M) | (3.53M) | (4.63M) | (5.13M) |
| Capital Expenditures | (81.6K) | (79.3K) | (51.76K) | (92.04K) | (5.32K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (81.6K) | (79.3K) | 0 | 0 | 0 |
| Investing Cash Flow | (81.6K) | (79.3K) | (51.76K) | (92.04K) | (5.32K) |
| Debt Repayment | (1.63M) | (17.8K) | 2.09M | 8.69M | (21.62K) |
| Common Stock Issued | 6.42M | 0 | 2.61M | 8.41M | 5.42M |
| Common Stock Repurchased | (104.47K) | (119.01K) | 0 | (149K) | 0 |
| Dividends Paid | (196.59K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.14M | 296.88K | 0 | 69 | 0 |
| Financing Cash Flow | 7.63M | 160.07K | 2.09M | 8.54M | 5.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.74M | (2.91M) | (1.49M) | 3.82M | 263.14K |
| Free Cash Flow | (2.89M) | (3.07M) | (3.58M) | (4.72M) | (5.13M) |
Nutriband Inc.
NASDAQ:NTRB
Intrinsic Alpha fair value
Locked
Current Price
$4.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.